- Benzinga•11 days ago
Esperion Therapeutics Inc (NASDAQ: ESPR ) reported encouraging top line results from its Phase 2 -035 and Phase 1 -037 trials, which Credit Suisse’s Vamil Divan believes addresses questions regarding the ...
- GlobeNewswire•12 days ago
1002-035 Study Meets Primary Endpoint of Incremental LDL-C Lowering Added to Atorvastatin 80 mg Bempedoic Acid Had No Effect on the PK of Atorvastatin and Was Observed to be Safe and Well-Tolerated Conference ...
Esperion Therapeutics, Inc. (ESPR)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||7.13 x 100|
|Day's Range||11.94 - 12.49|
|52wk Range||9.58 - 30.41|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-4.98|
|Avg Vol (3m)||353,016|
|Dividend & Yield||N/A (N/A)|